Modified release terbutaline (SKP1052) for hypoglycaemia prevention: A proof-of-concept study in people with type 1 diabetes mellitus.
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2013
At a glance
- Drugs Terbutaline (Primary)
- Indications Hypoglycaemia; Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 14 Aug 2013 New trial record